Welcome to Double Bond Pharmaceutical website. Our mission is to provide patients with more efficient and safer products in areas where their needs are not met. To this end, Double Bond Pharmaceutical’s scientific team has been working hard to overcome the drawbacks of widely available treatment options that have already proven their effectiveness. We focus on the redevelopment of known drugs by changing the route of administration to develop new formulations designed to reduce side effects and improve efficacy. Our vision is that medicines work best when they are delivered to the right place at the right time.
Welcome to Double Bond Pharmaceutical website. Our mission is to provide patients with more efficient and safer products in areas where their needs are not met. To this end, Double Bond Pharmaceutical’s scientific team has been working hard to overcome the drawbacks of widely available treatment options that have already proven their effectiveness. We focus on the redevelopment of known drugs by changing the route of administration to develop new formulations designed to reduce side effects and improve efficacy. Our vision is that medicines work best when they are delivered to the right place at the right time.
Our Products
At Double Bond Pharmaceutical, our areas of expertise are brain cancer, liver cancer and pneumonia. We have developed ways to treat these diseases much more effectively with our drug delivery system.
At Double Bond Pharmaceutical, our areas of expertise are brain cancer, liver cancer and pneumonia. We have developed ways to treat these diseases much more effectively with our drug delivery system.
SI-053 is a temozolomide gel that is administered locally into the cavity created after resection of glioblastoma.
SI-053 is a temozolomide gel that is administered locally into the cavity created after resection of glioblastoma.
BeloGal® is a drug delivery system based on biomimetic encapsulation of the active pharmaceutical ingredient with a polymer- and biology-free excipient that radically increased the therapeutic effect while protecting the remaining healthy tissues from toxic effects.
We also utilize an innovative hydrogel to allow the delivery of active pharmaceutical ingredients to the resection cavity in the brain.
BeloGal® is a drug delivery system based on biomimetic encapsulation of the active pharmaceutical ingredient with a polymer- and biology-free excipient that radically increased the therapeutic effect while protecting the remaining healthy tissues from toxic effects.
We also utilize an innovative hydrogel
to allow the delivery of active pharmaceutical ingredients to the resection cavity in the brain.
SA-033 is a novel treatment of cancers in liver. It is the first drug candidate that our company has developed using our first-in-class technology BeloGal®, which enables direct targeting of a drug to the selected organ, which in the case of SA-033 means that doxorubicin is targeted directly to the liver.
SA-033 is a novel treatment of cancers in liver. It is the first drug candidate that our company DBP has developed using our first-in-class technology BeloGal®, which enables direct targeting of a drug to the selected organ, which in the case of SA-033 means that doxorubicin is targeted directly to the liver.
Belopenem is based on BeloGal® and selectively directs the broad spectrum antibiotic meropenem to the infected lungs of pneumonia patients.
Belopenem is based on BeloGal® and selectively directs the broad spectrum antibiotic meropenem to the infected lungs of pneumonia patients.